CRISPR-Cas9 technology has revolutionized genetic research by providing scientists with a powerful tool to edit the genomes of various organisms, both prokaryotic and eukaryotic. This innovative technology enables precise modifications, such as the addition, removal, or alteration of DNA sequences, unlocking a plethora of possibilities across different fields.
In agriculture, CRISPR-Cas9 has emerged as a game-changer, offering the potential to enhance crop characteristics. Scientists can engineer crops with increased yields, improved resistance to diseases, and heightened nutritional content. This has the potential to address global challenges in food production and sustainability.
Moving into the realm of human health, CRISPR-Cas9 has made significant strides in applications like immunotherapy, gene therapy, and drug discovery. In immunotherapy, the technology allows for the targeted modification of immune cells, presenting a promising approach for more effective cancer treatments. Gene therapy, on the other hand, benefits from CRISPR-Cas9's precision, enabling the correction of genetic defects and opening new avenues for treating a variety of genetic disorders.
The pharmaceutical industry has taken notice of CRISPR-Cas9's potential, with major companies such as Novartis, Pfizer, and AstraZeneca forging partnerships with equity firms and academia. These collaborations aim to explore and validate the full capabilities of CRISPR-Cas9 in drug development and therapeutic interventions, signaling a collective recognition of its transformative impact.
The efficiency of CRISPR-Cas9 in transgenic research, combined with its streamlined screening and target validation processes, has positioned the technology as a cornerstone in modern genetic studies. Its user-friendly nature and versatility have accelerated its adoption across diverse fields, contributing to its rapid integration into mainstream scientific research.
As CRISPR-Cas9 applications continue to diversify and expand, market analysts predict substantial growth in the coming years. Its potential to revolutionize agriculture, human health, and drug discovery has positioned it as a key player in the biotechnology landscape. The technology's precise and efficient genome-editing capabilities promise groundbreaking discoveries and innovations, marking a paradigm shift in how we approach genetic manipulation and scientific research.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2022 | USD 3.2 Billion |
Market Size Value In 2023 | USD 3.5616 Billion |
Growth Rate | 11.30%(2023-2032) |
The CAS9 Technology Market Size was valued at USD 3.2 billion in 2022. The CAS9 Technology market industry is projected to grow from USD3.5616 Billion in 2023 to USD 8.386996414 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.30% during the forecast period (2023 - 2032).Increased awareness regarding biotechnology techniques and products and the increasing acceptance of gene therapy-based treatments are the major driving factors for the CAS9 technology market growth and are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
There has been a notable increase in investment and funding from governments specifically directed towards CRISPR technology. This has created a conducive environment for research and development in the field, enabling breakthrough discoveries and propelling the market forward. For instance, in February 2023, Indian biotechnology start-up CrisprBits raised $250,000 in pre-seed funding from US-based VJ Group. The funding will be used to develop products, expand the team and invest in research and development. CrisprBits plans to develop CRISPR- based diagnostics to detect pathogens and antimicrobial resistance genes. This factor drives the market CAGR.
Additionally,the development of new vaccines and treatments for genetic diseases using CRISPR technology presents a transformative opportunity in the field of healthcare. CRISPR's precise gene editing capabilities hold immense potential in combating infectious diseases and addressing the underlying genetic causes of various disorders. This opportunity promises innovative approaches to prevent and treat diseases and revolutionizes how we approach healthcare interventions. For instance, Editas Medicine is conducting a phase 1/2 trial for individuals with severe sickle cell disease (SCD) but using a CRISPR system with a Cas12a protein rather than the more famous Cas9 protein. Moreover, Vertex Pharmaceuticals and CRISPR Therapeutics are working together on Beta-thalassemia. The clinical trial is in its second phase.
Furthermore, the quality of medicine can be significantly improved by using CRISPR technology to create a variety of medications. It can be utilised to create medications for cardiac conditions and blood issues. The market for CRISPR technology is expanding as a result of the technology's rising rate of adoption. The cost of CRISPR technology rises because to its complexity and sophisticated nature, further limiting its development. The increases in the availability of Government and private funding are the main reasons driving the market's growth. Furthermore, there is a rise in the number of cases of genetic disorders, and there is a need for advanced therapies such as CRISPR technology, which can be used to treat cancer, influencing market growth.Thus, driving the CAS9 Technology market revenue.
Based on product type, the CAS9 Technology market segmentation includes consumables and vectors. The consumables segment dominated the market; consumables play a crucial role in the workflow and implementation of CAS9 technology. These include reagents, enzymes, and other essential components necessary for the CRISPR-Cas9 gene editing process. As CAS9 technology continues to gain prominence in various research and biotechnology applications, the demand for consumables rises accordingly.
The CAS9 Technology market segmentation, based on Application, includes genome engineering, disease models, and in vitro genetic depletion. The genome engineering segment dominated the market; the increasing adoption of CAS9 technology in academic and research institutions further strengthens the dominance of the Genome Engineering segment. Scientists and researchers across diverse disciplines recognize the power and versatility of CAS9 technology in studying gene functions, unraveling disease mechanisms, and exploring new avenues for discovery.
The CAS9 Technology market segmentation, based on delivery methods, includes physical delivery methods, viral delivery methods, and non-viral delivery method. The viral delivery methods segment dominated the market; viral delivery methods offer high efficiency in delivering the CRISPR-Cas9 components into target cells. Viral vectors, such as lentiviruses and adeno-associated viruses (AAVs), have evolved to efficiently infect many cell types, making them highly effective tools for gene editing applications. Their ability to deliver the CRISPR-Cas9 system to the desired cells ensures successful gene editing and manipulation.Furthermore, viral delivery methods benefit from their ability to achieve long-lasting gene expression and stable integration of the CRISPR-Cas9 system into the host cell's genome.
Based on end users, the CAS9 Technology market segmentation includes Biotechnology & Pharmaceutical Companies and Academic & Research Institutes. The biotechnology & pharmaceutical companies' segment dominated the market; the growing demand for innovative and targeted therapies is a major driver for pharmaceutical and biotechnology companies in the CRISPR market. CRISPR technology enables precise gene editing, offering the potential to develop personalized medicines for genetic diseases. North America was the largest market for the CRISPR industry in 2023.
Figure1: Global CAS9 Technology Market, byEnd User, 2022 & 2032(USD billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American CAS9 technology market will dominate due to strict regulations for manufacturing medical devices and providing medical services, which improves the quality of devices and technology and will boost the market growth in this Region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure2: CAS9 TECHNOLOGY MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe CAS9 Technology market accounts for the second-largest market share due to theincreased investment in developing innovative solutions to treat genetic diseases by government-aided, run, and established bodies and centers. Further, the German CAS9 Technology market held the largest market share, and the UK CAS9 Technology market was the fastest-growing market in the European Region.
The Asia-Pacific CAS9 Technology Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due tothe explanation of the biotechnology industry and the rapid implementation of advanced technologies, such as CAS9 is driving regional growth. Moreover, China’s CAS9 Technology market held the largest market share, and the Indian CAS9 Technology market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the CAS9 Technology market, grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the CAS9 Technology industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the CAS9 Technology industry to benefit clients and increase the market sector. The CAS9 Technology industry has offered some of the most significant medical advantages in recent years. Major players in the CAS9 Technology market, includingCellecta, Inc., abm Inc., GenScript, CRISPR Therapeutic, Intellia Therapeutics, Inc., GE Healthcare, Takara Bio, Inc., AstraZeneca, PLC, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), New England Biolabs, OriGene Technologies, Inc., Lonza Group, and Thermo Fisher Scientific., and others, are attempting to increase market demand by investing in research and development operations.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for various rare and common diseases. Using the gene-editing technique CRISPR/Cas9, CRISPR Therapeutics and Vertex Pharmaceuticals are extending their current partnership to create medicines for hereditary illnesses that cause muscular weakness.
A biotechnology business in the trial stages called Intellia treatments is dedicated to creating cutting-edge, possibly curative treatments using CRISPR-based technologies.Intellia Therapeutics and Novartis stated their relationship will be extended to encompass the ex vivo creation of novel cell treatments employing specific ocular stem cells.
The wild-type MAD7 CRISPR Type-V nuclease, Eureca-V Nuclease, was released in 2021 at Research Grade by Aldevron, which develops and produces plasmid DNA, RNA, and proteins for the biotech industry. GMP will follow. The introduction of Eureca-V Nuclease by Aldevron during Advanced Therapies Week broadens the range of CRISPR nucleases accessible for therapeutic, diagnostic, and agricultural workflows.
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that they have signed a new non-exclusive licencing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to quicken the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D). The agreement will go into effect in 2023.
In November 2022, Vertex and CRISPR Therapeutics began submitting exa-cel for beta thalassemia and sickle cell disease. In two recently released reports, IDC MarketScape for Worldwide Manufacturing Service Life-Cycle Management Strategic Consulting and IDC MarketScape for Worldwide Manufacturing Service Life-Cycle Management Systems Integrators/Business Process Outsourcing, Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) has been positioned as a Leader in 2023.
Siemens and IBM are extending their collaboration in 2023 to hasten the creation of sustainable products and business practises. From systems engineering through service and asset lifecycle management, the digital thread.
The market's top Configuration Lifecycle Management (CLM) platform, Configit Ace®, was made accessible as a cloud service in 2023, according to Configit. Any IT system can be integrated with the cloud-based Configuration Lifecycle Management (CLM) platform, which is vendor-neutral.
Consumables
Vectors
Genome Engineering
Disease Models
In Vitro Genetic Depletion
Physical Delivery Methods
Viral Delivery Methods and Non-Viral
Delivery Methods
Biotechnology & Pharmaceutical Companies
Academic & Research Institutes
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)